Breaking News

Celerion Names Translational Medicine Director

May 21, 2013

Morimoto brings more than 20 years of experience

Dr. Bruce Morimoto has been appointed executive director of Applied Translational Medicine at Celerion. Dr. Morimoto is responsible for developing and implementing strategies for patient populations in early clinical research and clinical pharmacology studies. Dr. Morimoto will also lead the external studies management and clinical monitoring services teams.
Dr. Morimoto has more than 20 years of experience in the pharmaceutical and biotechnology, and CRO industries. He joins the company from Allon Therapeutics, where he served as vice president of drug development. His focus was to manage Allon’s neurodegeneration and dementia therapeutic programs including preclinical, manufacturing and clinical development. Dr. Morimoto also held positions at MDS Pharma Services, Neuromed Technologies, Phoenix International Life Sciences, and Amur Pharmaceuticals.
“We are very pleased to have Bruce join the Drug Development Services team at Celerion,” said Susan Thornton Ph.D., president and chief executive officer of Celerion. “His in-depth knowledge of drug development as well as focus on Applied Translational Medicine from both the client and CRO perspective will be a great asset to our organization.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important